Trials / Recruiting
RecruitingNCT07300293
Lactic Acidosis and Prior Metformin Treatment
Prognosis of Lactic Acidosis Upon Admission to Intensive Care According to the Existence of Prior Treatment With Metformin
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Metformin is a drug frequently prescribed to patients with type 2 diabetes. Furthermore, diabetes can lead to micro- and macrovascular complications that may cause chronic organ failure. The presence of diabetes also increases the risk of infections. All of these factors contribute to the frequent admission of patients to the ICU who have been receiving metformin treatment in the preceding days. Acute renal failure, which is also frequently observed upon admission to the ICU, increases the risk of metformin overdose. In cases of overdose, metformin acts on several metabolic pathways that can lead to or even accelerate metabolic acidosis, sometimes severe. However, the impact on prognosis is controversial. The role of metformin in lactic acidosis in patients treated for acute illness may be underestimated in routine practice. This study aims to investigate the impact of prior metformin treatment on ICU survival in patients admitted to the ICU with severe lactic acidosis.
Conditions
Timeline
- Start date
- 2024-11-06
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2025-12-23
- Last updated
- 2025-12-23
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT07300293. Inclusion in this directory is not an endorsement.